Evidence map›Paper›PMID 35672552›Full record

ArticleAIDS and behavior2022

A PrEP Demonstration Project Using eHealth and Community Outreach to Justice-Involved Cisgender Women and Their Risk Networks.

Jaimie P Meyer, Carolina R Price, Yiwen Ye, Yilu Qin, DeShana Tracey, A C Demidont, Kathleen Melbourne, Frederick L Altice

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in AIDS and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03293290 phase1completednot on this map

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

TypeinterventionalSponsorYale UniversityRan2017 to 2020Enrolled105ConditionsHIV InfectionsArmsPrEP
NCT06411223 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

Project Tara: Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

TypeinterventionalSponsorYale UniversityRan2024 to 2027Enrolled50ConditionsHivArmsCollaborative drug therapy management model, Cabotegravir/Rilpivirine
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jaimie P MeyerYale School of Medicine, AIDS Program, 135 College Street, Suite 323, 06510, New Haven, CT, United States. Jaimie.meyer@yale.edu.ORCID http://orcid.org/0000-0001-5735-385X
Carolina R PriceYale School of Medicine, AIDS Program, 135 College Street, Suite 323, 06510, New Haven, CT, United States.
Yiwen YeYale School of Public Health, Chronic Disease Epidemiology, New Haven, CT, United States.
Yilu QinPrimary Care Program, Yale New Haven Health, HIV Training Track, New Haven, CT, United States.
DeShana TraceyYale School of Medicine, AIDS Program, 135 College Street, Suite 323, 06510, New Haven, CT, United States.
A C DemidontGilead Sciences, Inc, Foster City, CA, United States.
Kathleen MelbourneGilead Sciences, Inc, Foster City, CA, United States.
Frederick L AlticeYale School of Medicine, AIDS Program, 135 College Street, Suite 323, 06510, New Haven, CT, United States.
Yale University · USGilead Sciences (United States) · USYale New Haven Health System · US

Funding

Gilead Sciences Gilead Sciences
6 · The paper itself

Abstract

Women involved in criminal justice systems (WICJ) are a key population at risk for HIV, and pre-exposure prophylaxis (PrEP) is critical for HIV prevention. This project was designed to evaluate the feasibility and acceptability of delivering PrEP via eHealth to WICJ and members of their risk network (RN). We recruited HIV-negative cisgender WICJ index participants (n = 38) and risk network (RN) members (n = 67) using modified respondent-driven sampling. TDF/FTC was initiated for PrEP in participants meeting clinical criteria and dispensed through eHealth using a community-based, low barrier-to-care outreach model. Key steps in the PrEP care continuum were measured over 12 months. Enrolled participants (n = 105) had high current and lifetime justice-involvement and were predominantly cisgender women and non-Hispanic white with a mean age of 40.9y (SD 9.6). Despite most having primary care providers and medical insurance, PrEP awareness was low, and participants experienced high levels of medical, psychiatric, substance use, social, and economic need. Fifty-two participants (50%) were PrEP-eligible, of whom 24 (46%) initiated PrEP. TDF/FTC was safe and well-tolerated throughout follow-up and 13 individuals chose to remain on PrEP following study conclusion. In this novel PrEP demonstration project for WICJ and RN members, despite high medical, psychiatric, and social comorbidity, PrEP was positively received and effectively delivered using a community outreach model via eHealth.Registered on clinicaltrials.gov under trial registration number NCT03293290.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisTelemedicineAdultCommunity-Institutional RelationsFemaleHumansAnti-HIV AgentsCisgender womenCriminal justiceHIV preventionPrEP

Identifiers

PMID35672552
OpenAlexW4281964453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.